Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2025 07:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics Announces FDA Clearance of Investigational New Drug Application for EVOLVE104, a Novel Trispecific T Cell Engager with Integrated CD2 Costimulation

First Program from EVOLVE T-Cell Engager Platform to Advance into Clinical Development Phase 1 Clinical Trial of EVOLVE104 to be Initiated in 2025 BRANFORD, Conn., Aug. 14, 2025 (GLOBE NEWSWIRE)...
April 08, 2025 07:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics Announces Translational Research Collaboration to Evaluate Expression of Novel Tumor Target in Muscle-Invasive Bladder Cancer

BRANFORD, Conn. and NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing next-generation T cell engager biotherapeutics to overcome cancer...
November 11, 2024 07:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics Presents New Preclinical and Translational Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Poster Presentations Spotlight Differentiated Therapeutic Profile and Precision Therapeutic Strategy for Lead Development Candidate EVOLVE104 as Program Advances Toward Clinic for Solid Tumors EVOLVE...
October 31, 2024 08:00 ET | Source: EvolveImmune

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to...
October 23, 2024 07:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics to Present New Preclinical Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Multiple Presentations on Lead Development Candidate EVOLVE104 to Showcase Preclinical Safety and Efficacy Profile and Precision Therapeutic Strategy as Company Advances Program Toward Clinic for...
December 13, 2023 07:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics Provides Corporate and Program Update Highlighted by Closing of $37 Million Financing

Fundraising Includes Strategic Investment by Bristol Myers Squibb Coupled with Support from Existing Investors EvolveImmune Initiates Chemistry, Manufacturing, and Control (CMC) Activities for Lead...
November 06, 2023 07:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics Presents New Preclinical and Translational Data on Novel CD2 Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

BRANFORD, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome the therapeutic...
October 18, 2023 07:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics to Present New Preclinical and Translational Data Highlighting Precision Medicine Potential of its Novel Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

EvolveImmune to Highlight New Data on Precision Medicine Potential of Evolve Platform and Lead Development Programs in Presentations at SITC 2023
June 14, 2023 07:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics Enters into Strategic Research Collaboration with Kennedy Institute of Rheumatology

BRANFORD, Conn., June 14, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven...
April 18, 2023 09:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023

Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1 Checkpoint Pathway Engineered CAR-T Cells Lacking Exhaustion-Associated Genes Mediate Improved...